Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Lipocine has initiated subject dosing in a two-arm, blinded, randomised Phase III trial of LPCN 1154 for postpartum ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).

Kashiv has reported positive topline outcomes from the confirmatory trial of the proposed biosimilar to Novartis’ Xolair, ADL ...

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of Ajovy (fremanezumab).